Immunotherapy for Hematologic Diseases: An Investigation of the Role of HLA Genes in Support of HSCT inPatients with AML and ALL

Immunotherapy is a potential treatment against hematopoietic malignancies and an innovative field that hasbeen growing in recent years. In the present study, the researcher targeted to investigate the correlationbetween HLA (specified genes) and patients with AML and ALL. The study was performed on ۹۱ patients withacute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) using PCR-SSP for HLA typing, whounderwent HSCT at cell therapy and bone marrow transplantation centers in Iran. In addition, there was a donorgroup for the final comparison. Results revealed that there was an increased frequency of HLA-A*۳۲ antigen inAML patients in comparison to the donor group. Moreover, decreased frequencies of HLA-B*۱۴ was noted inAML patients. In addition, HLA-A*۲۵ and HLA-DRB۱*۰۴ were detected to be risk factors in pediatrics with ALL.Furthermore, it was observed that the frequencies of HLA-B*۵۵ in both ALL and AML patients were decreased.The findings indicate that two class I HLA antigens (HLA-A*۳۲; HLA-A*۲۵) and one class II antigen (HLA-DRB۱*۰۴)might serve as a genetic predisposing factor. Additionally, one class I antigen (HLA-B*۵۵) appears to be apotential protective factor against both ALL and AML patients.

کلیدواژه ها:

Immunotherapy ، acute myeloid leukemia ، acute lymphoblastic leukemia